|
SLC25A46 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.84741111297626E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.19102513909775E-12 |
| Normal-vs-Stage2 |
2.098700E-03 |
| Normal-vs-Stage3 |
2.94853030879949E-12 |
| Normal-vs-Stage4 |
5.11102271616437E-12 |
| Stage1-vs-Stage2 |
1.065420E-01 |
| Stage1-vs-Stage3 |
1.695230E-01 |
| Stage1-vs-Stage4 |
5.731800E-02 |
| Stage2-vs-Stage3 |
2.584500E-02 |
| Stage2-vs-Stage4 |
7.535800E-03 |
| Stage3-vs-Stage4 |
4.401200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.04281036531029E-14 |
| Normal-vs-AfricanAmerican |
3.4744000000364E-06 |
| Normal-vs-Asian |
2.70230005039451E-09 |
| Caucasian-vs-AfricanAmerican |
8.187600E-01 |
| Caucasian-vs-Asian |
8.244600E-01 |
| AfricanAmerican-vs-Asian |
7.143800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.38510330877284E-11 |
| Normal-vs-Female |
3.16335846406446E-12 |
| Male-vs-Female |
4.851800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.70950031908035E-10 |
| Normal-vs-Age(41-60Yrs) |
4.39293046383682E-12 |
| Normal-vs-Age(61-80Yrs) |
1.40019995598095E-09 |
| Normal-vs-Age(81-100Yrs) |
1.538820E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.634000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.295000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.648600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.840200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.488400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.884200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.290760E-01 |
| Classical-VS-Follicular |
1.960990E-01 |
| Classical-VS-Other |
1.925620E-01 |
| Classical-VS-Normal |
1.84885440290827E-12 |
| Tall-VS-Follicular |
1.912100E-02 |
| Tall-VS-Other |
5.400600E-01 |
| Tall-VS-Normal |
2.47630005389965E-09 |
| Follicular-VS-Other |
2.490200E-02 |
| Follicular-VS-Normal |
1.71719999999542E-05 |
| Other-VS-Normal |
1.163990E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.83510001533693E-10 |
| Normal-vs-N1 |
5.65599789226212E-11 |
| N0-vs-N1 |
1.221250E-01 |
|
|
